ProtoKinetix Childhood Diabetes Initiative Strengthened by Addition to Scientific Advisory Board
PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, January 25, 2010
ProtoKinetix, Inc. (PKTX) board of directors announces the appointment of Dr. John Hutton Phd, to their Scientific Advisory Board which is headed up by General Dr. John Parker. Dr. Hutton is the internationally recognized Director of Research at the Barbara Davis Center for Childhood Diabetes.
This opportunity to collaborate with the Director of Research for this prestigious institution enhances the ability of ProtoKinetix to prove the value of AAGPTM in Type 1 Diabetes treatment. PKTX is currently focusing on demonstrating the pivotal role that AAGPTM will play in many of the more promising treatments for Type 1 Diabetes being developed around the world.
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycoproteins (AAGPTM) for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialogue with major corporations and institutions who have contacted the company about the broad range of applications for AAGPTM products.
For more detailed information, please visit our website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
Ross L. Senior, President and CEO
Suite # 1500 2225 Folkestone Way
West Vancouver, BC
Email: [email protected]